Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment

by palligoelme@gmail.com | Mar 11, 2026 | Clinical Trials

​ Conditions: Bioequivalence Study in Healthy Subjects Interventions: Drug: Rivastigmine TDS 9,5 mg/24 h; Drug: Exelon® 9.5 mg/24 h Sponsors: Zodiac Produtos Farmaceuticos S.A. Completed Conditions: Bioequivalence Study in Healthy Subjects Interventions: Drug:...

Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia

by palligoelme@gmail.com | Mar 11, 2026 | Clinical Trials

​ Conditions: Autonomic Dysreflexia; Spinal Cord Injuries and Disorders (SCI/D); Cardiac Remodeling Sponsors: Swiss Paraplegic Research, Nottwil Not yet recruiting Conditions: Autonomic Dysreflexia; Spinal Cord Injuries and Disorders (SCI/D); Cardiac Remodeling...

Assesment of the Clinical Benefit of Provocation on Tilt-table in SYNCope Patients, TiltSYNC-trial

by palligoelme@gmail.com | Mar 11, 2026 | Clinical Trials

​ Conditions: Vasovagal Syncope (VVS) Interventions: Diagnostic Test: biofeedback and standard of care with tilt table testing; Diagnostic Test: no tilt table testing Sponsors: Academisch Medisch Centrum – Universiteit van Amsterdam (AMC-UvA)...

The Influence of Anemia on HbA1c Readings in Non-Diabetic Patients

by palligoelme@gmail.com | Mar 11, 2026 | Clinical Trials

​ Conditions: Anemia; HbA1c Sponsors: Sohag University Not yet recruiting Conditions: Anemia; HbA1c Sponsors: Sohag University Not yet recruiting 

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

by palligoelme@gmail.com | Mar 11, 2026 | Clinical Trials

​ Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of the Head and Neck Interventions: Drug: Ficerafusp alfa; Drug: Pembrolizumab Sponsors: Dana-Farber Cancer Institute; Bicara Therapeutics Not yet recruiting Conditions: Head and Neck...